Table 1.
Interventional studies registered at the ClinicalTrials.gov database relating the treatment of COVID-19 with NET inhibitors.
| NCT identifier | Status | Location | Study type | Condition or disease | Intervention and phase | Primary outcome | Estimated completion date |
|---|---|---|---|---|---|---|---|
| NCT04409925 | Not yet recruiting | Canada | Nonrandomized pilot study | COVID-19 | Dornase Alfa Phase: 1 |
(1) Rate of all adverse events | January 2021 |
| NCT04359654 | Not yet recruiting | United Kingdom | Randomized clinical trial | COVID-19 Hypoxia |
Drug: Dornase Alfa Phase: 2 |
(1) Change in inflammation (C-reactive protein) | November 2020 |
| NCT04445285 | Recruiting | United States | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 |
(1) All-cause mortality (2) Systemic therapeutic response |
February 2021 |
| NCT04432987 | Recruiting | Turkey | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 |
(1) Clinical improvement and inflammatory markers in blood (2) Intubation or extubation |
September 2020 |
| NCT04402944 | Not yet recruiting | United States | Randomized clinical trial | COVID-19 | Dornase Alfa Phase: 2 |
(1) Ventilator-free days | December 2021 |
| NCT04322565 | Recruiting | Italy | Randomized clinical trial | COVID-19 Pneumonia |
Colchicine Phase: 2 |
(1) Clinical improvement (2) Hospital discharge |
December 2020 |
| NCT04326790 | Recruiting | Greece | Randomized clinical trial | COVID-19 | Colchicine Phase: 2 |
(1) Time to clinical deterioration (2) Concentration of cardiac troponin |
September 2020 |
| NCT04402970 | Recruiting | United States | Nonrandomized clinical trial | COVID-19 ARDS |
Dornase Alfa Phase: 3 |
(1) Improvement in partial pressure of O2 to fraction of inspired O2 ratio | May 2022 |
| NCT04355364 | Recruiting | France | Randomized clinical trial | COVID-19 ARDS |
Dornase Alfa Phase: 3 |
(1) Occurrence of at least one grade improvement (ARDS scale severity) | August 2020 |
| NCT04322682 | Recruiting | United States | Randomized clinical trial | COVID-19 | Colchicine Phase: 3 |
(1) Number of participants who die or require hospitalization | December 2020 |
| NCT04328480 | Recruiting | Argentina | Randomized clinical trial | COVID-19 | Colchicine Phase: 3 |
(1) Number of participants who die (all-cause mortality) | August 2020 |
Retrieved October 30, 2020, from https://www.https://www.clinicaltrials.gov/ct2/home. Abbreviations: NCT: National Clinical Trial; O2: oxygen; ARDS: acute respiratory distress syndrome.